Type I reaction in lepromatous patients ten years after cure
Vol. 26 No. 2 (2001), Estudos clínicos
Vol. 26 No. 2 (2001)

Type I reaction in lepromatous patients ten years after cure

Estudos clínicos
https://doi.org/10.47878/hi.2001.v26.36406
Published 2001-11-30
Somei Ural
Médico dermatologista e Pesquisador cientifico - Instituto Lauro de Souza Lima - Secretaria de Estado da Saúde - Bauru - SP
Diltor Vladimir Araujo Opromolla
Medico dermatologista e Diretor da Divisão de Pesquisa e Ensino - Instituto Lauro de Souza Lima - Secretaria de Estado da Saúde.
Deise Aparecida dos Santos Codoy
Médica dermatologista - Instituto Lauro de Souza Lima - Secretaria de Estado da Saúde.
Raul Negrão Fleury
Médico anátomo patologista e pesquisador cientifico - Instituto Lauro de Souza Lima - Secretaria de Estado da Saúde.
PDF (Português (Brasil))

Keywords

Lepromatous leprosy
borderline leprosy
type I reaction
immunotherapy

How to Cite

1.
Ural S, Opromolla DVA, Codoy DA dos S, Fleury RN. Type I reaction in lepromatous patients ten years after cure. Hansen. Int. [Internet]. 2001 Nov. 30 [cited 2024 Nov. 22];26(2):117-20. Available from: https://periodicos.saude.sp.gov.br/hansenologia/article/view/36406
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

A case of lepromatous leprosy patient treated with rifampin and dapsone for six months, and then treated with dapsone only for 14 years, is presented. The patient remained without lesions and with negative bacilloscopy for 10 years, and after this period he started again to show lesions, now with borderline aspect and appearance of bacilli. The authors suggest that the patient has always been a borderline whose disease has become more severe to the point that he presented a lepromatous aspect. When bacilli started to show up again, the patient's cellular immunity destroyed them so that borderline lesions appeared, as it must have happened in the initial phase of the disease. They also discuss the possible causes that led bacilli, probably persistent, to multiply again.

https://doi.org/10.47878/hi.2001.v26.36406
PDF (Português (Brasil))

References

1 CONVIT, J. et al. Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and Mitsuda negative contacts. Intl. Leprosy, v.50, p.415-424, 1982.
2 MACKAY, I. R., M.D.; ROSEN, E S., M.D. Maternal antibodies, chilhood infections, and autoimmune diseases. New Engl. J. Med., v.345, n.18, p.1331-1335, 2001.
3 OPROMOLLA, D. V. A. et al. A controlled trial to compare the therapeutic effects of Dapsone in combination with daily or once- monthly rifampicin in patients with lepromatous leprosy. Int J. Leprosy, v.49, n.4, p.393-397, 1981.
4 WORLD HEALTH ORGANIZATION. Subcommittee on clinical trials of the chemotherapy of leprosy (THELEP) scientific working group of the UNDP/Word bank / WHO Special Programme for the research and training in tropical disemPq. Persisting Mycobacterium leprae among THELEP trials patients in Bamako and Chingleput. Leprosy Rev., v.58, p.325-337, 1987.
5 YAWALKAR, S. J. et al. Once-monthly rifampicin plus daily dapsone in initial treatment Iepromatous leprosy Lancet, n.8283, p.1199- 1202, May, 1982.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Downloads

Download data is not yet available.